Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT05328245 Completed - Clinical trials for Irritable Bowel Syndrome

Internet-delivered Exposure-based Cognitive Behavior Therapy for Irritable Bowel Syndrome - a Cohort Effectiveness Study

Start date: April 1, 2015
Phase:
Study type: Observational

The main purpose of the study is to investigate the clinical real-world effectiveness of a specific exposure based psychological treatment for irritable bowel syndrome (IBS). A secondary aim of the study is to find mediators of the treatment effect and thereby learn something about the working mechanism of the treatment.

NCT ID: NCT05324761 Completed - Clinical trials for Failed Back Surgery Syndrome

Management of Pain Associated With Failed Back Surgery Syndrome

Start date: April 25, 2022
Phase: Phase 4
Study type: Interventional

Neuropathic pain is a common complication following different types of spine surgery making negative impact on health, along with life style changes and management, many neurologist prescribed either Pregabalin or Gabapentin to manage this condition with overall good results. our study aims to evaluate the efficacy of Pregabalin and Gabapentin in the management of this condition and to compare between them

NCT ID: NCT05324176 Completed - Myasthenia Gravis Clinical Trials

Diaphragm Thickness by Ultrasonography in Neurological Disorders

Start date: April 13, 2022
Phase: N/A
Study type: Interventional

participants will be allocated into three groups, acute neuropathy (Guillain Barre Syndrome) group, neuromuscular junction disorder(myasthenia gravis ) group, and control group(people with neurological disorders not affecting the respiratory system.Ultrasonography is done on the diaphragm. The index test (ultrasound imaging of the diaphragm) is used. A high-resolution portable ultrasound machine is used, with a 7- to 13-MHz linear array transducer. Patients will be examined in the supine position. diaphragmatic thickness will is measured on both sides during a deep breath in inspiration and during expiration. objectives: primary outcome: to compare diaphragm thickness between the three examined groups. Secondary outcome: correlation between clinical scores and reference US values of diaphragm

NCT ID: NCT05322096 Completed - Clinical trials for Prader-Willi Syndrome

Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome

Start date: September 22, 2022
Phase: Phase 2
Study type: Interventional

RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management. This will be the first Phase 2, proof-of-concept study using RGH-706 and is the third study in the clinical development program for RGH-706. The aim of this study is to evaluate the efficacy, safety, and tolerability of RGH-706 in patients with Prader-Willi Syndrome (PWS).

NCT ID: NCT05321966 Completed - Quality of Life Clinical Trials

The Effect of Video Training on Symptom Burden Patients Undergoing Hemodialysis Treatment

Start date: April 15, 2021
Phase: N/A
Study type: Interventional

Purpose: This study aimed to examine the impacts of video training support on the symptom burden, comfort level and quality of life (QoL) of the patients undergoing hemodialysis (HD) treatment. Methods: The current study adopted a randomized controlled quasi-experimental research design to investigate the implications of video training support on the symptom burden, comfort level and QoL of 48 participant patients, 22 of whom were in control and 26 were in intervention group, at Mugla Fethiye State Hospital Hemodialysis Center and a private hemodialysis center between April 2021 and July 2021. Data collection was conducted through Dialysis Symptom Index (DSI), Patient Information Form, QoL Scale Short Form (SF 36), and Hemodialysis Comfort Scale (HDCS) Version II. The data was collected four times, in week 0 (1st measurement), 4th week (2nd measurement), 8th week (3rd measurement), and 12th week (4th measurement). The intervention group watched three episodes of a training video a week for 12 weeks. Each session started 90 minutes after the HD treatment. The control group was shown the training video at the end of the research. Necessary ethics committee, institutional permissions and written consents of the participant patients were obtained prior to the study.

NCT ID: NCT05320601 Completed - Clinical trials for Myofascial Pain Syndrome

Efficacy of Peripheral Magnetic Stimulation Compare to Dry Needling in Myofascial Pain Syndrome

Start date: April 11, 2022
Phase: N/A
Study type: Interventional

Compare efficiency between repetitive peripheral magnetic stimulation and dry needling in patient with upper trapezius myofascial pain syndrome.

NCT ID: NCT05320289 Completed - Clinical trials for Polycystic Ovary Syndrome

Feasibility Study of the AblaCare System in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With Infertility Due to Polycystic Ovary Syndrome

ULTRA-US
Start date: May 12, 2022
Phase: N/A
Study type: Interventional

The objective of the study is to provide preliminary evidence for the safety and effectiveness of the AblaCare System in transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome (PCOS) who have not responded to first-line ovulation induction treatment or are contraindicated for or decline such treatment.

NCT ID: NCT05317286 Completed - Clinical trials for Acute Coronary Syndrome

LVEF Prediction During ACS Using AI Algorithm Applied on Coronary Angiogram Videos

CathEF
Start date: June 1, 2022
Phase:
Study type: Observational

Left ventricular ejection fraction (LVEF) is one of the strongest predictors of mortality and morbidity in patients with acute coronary syndrome (ACS). Transthoracic echocardiography (TTE) remains the gold standard for LVEF measurement. Currently, LVEF can be estimated at the time of the coronary angiogram but requires a ventriculography. This latter is performed at the price of an increased amount of contrast media injected and puts the patients at risk for mechanical complications, ventricular arrhythmia or atrio-ventricular blocks. Artificial intelligence (AI) has previously been shown to be an accurate method for determining LVEF using different data sources. Fur the purpose of this study, we aim at validating prospectively an AI algorithm, called CathEF, for the prediction of real-time LVEF (AI-LVEF) compared to TTE-LVEF and ventriculography in patients undergoing coronary angiogram for ACS.

NCT ID: NCT05313984 Completed - Fecal Incontinence Clinical Trials

OptiLUTS Part C: The Development of a Symptom Assessment Tool in Sacral Neuromodulation.

OptiLUTS
Start date: March 1, 2018
Phase:
Study type: Observational

Sacral neuromodulation (SNM) is a two-staged 2nd-line therapy for therapy-resistant LUTS and fecal incontinence. Currently, the assessment of symptoms at baseline and after stage I is directed towards a discipline related evaluation. The OptiLUTS trial strives for a more holistic approach, taking all pelvic floor dysfunctions into account. A holistic assessment tool will be developed and SNM-care pathway will be set-up.

NCT ID: NCT05312177 Completed - Clinical trials for Congenital Heart Disease

Congenital Heart Disease: Impact on Learning and Development in Down Syndrome (CHILD-DS)

CHILD-DS
Start date: May 1, 2022
Phase:
Study type: Observational

The study objective is to compare neurodevelopmental (ND) and behavioral outcomes between children with Down syndrome (DS) who had complete atrioventricular septal defect (CAVSD) repair and children from the same clinical sites with DS without major congenital heart disease (CHD) requiring previous or planned CHD surgery.